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In chronic obstructive pulmonary disease (COPD), worsening expiratory flow limitation together with alteration in
the elastic properties of the lung are associated with progressive lung hyperinflation and gradual decline in the
resting inspiratory capacity over time. Dynamic hyperinflation (DH) refers to the variable increase in end-expiratory
lung volume (EELV) above the relaxation volume (VR) of the respiratory system that occurs when expiratory flow
limitation is amplified (e.g., during bronchoconstriction and acute exacerbations) or when ventilation is increased
in the setting of expiratory flow limitation. During exercise, the combined factors of worsening expiratory flow
limitation, increasing respiratory neural drive and breathing pattern alterations dictate the pattern and extent of DH.
Acute-on-chronic hyperinflation increases the intrinsic loads on the inspiratory muscles which become functionally
weakened. The combined effects of compromised respiratory and integrated cardio-circulatory function due to lung
hyperinflation contribute to exercise limitation. In COPD, the resting inspiratory capacity, which indirectly reflects
the extent of lung hyperinflation, dictates the limits of tidal volume expansion and thus, peak ventilatory capacity
during activity. Moreover, the growing disparity between increased respiratory neural drive and the blunted
respiratory muscular/mechanical response due to lung hyperinflation is mechanistically linked to dyspnea during
exercise in COPD. From a clinical standpoint, measurement of lung hyperinflation is integral to the assessment of
physiological impairment in individuals with COPD and can effectively be targeted for treatment. Moreover, it is
now well established that lung volume reduction (deflation) provides a solid mechanistic rationale for observed
improvements in dyspnea and exercise tolerance in patients with COPD following bronchodilator therapy.
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Expiratory flow limitation (EFL) is generally regarded as
the pathophysiological hallmark of COPD [1]. Lung
hyperinflation is a related phenomenon that is of equal
clinical importance but less often considered [2]. Mea-
sures of resting lung hyperinflation have been shown to
be predictive of respiratory and all-cause mortality and
are needed to comprehensively characterize physio-
logical impairment in individual COPD patients [3, 4].
Dynamic lung hyperinflation (DH) refers to the variable
increase in end-expiratory lung volume (EELV) above
the relaxation volume (VR) of the respiratory system [1].
DH occurs when EFL is acutely worsened during
bronchospasm or exacerbation, often in the setting of* Correspondence: odonnell@queensu.ca
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creativecommons.org/publicdomain/zero/1.0/increased ventilation ( _VE) due to increased chemostimu-
lation and respiratory neural drive [5]. Depending on the
extent of resting lung hyperinflation, further DH when
the respiratory system is stressed can have important
negative consequences for the function of both the re-
spiratory and cardio-circulatory systems [6]. Moreover,
acute DH is increasingly implicated as a major cause of
dyspnea – the dominant symptom in patients with
chronic airway diseases [7]. In this concise review we
will attempt to: a) clarify definitions of lung hyperinfla-
tion; b) review causative mechanisms; c) consider its nat-
ural progression and negative clinical consequences,
particularly concerning its role in exercise limitation and
dyspnea causation in COPD; and d) summarize the clin-
ical benefits of pharmacological lung volume reduction.s article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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For the purpose of this review, an increase in total lung
capacity (TLC) (preferably measured by body plethysmog-
raphy) exceeding either the upper limit of normal (ULN) or
an empiric 120 % of predicted is consistent with thoracic
hyperinflation. An increase in plethysmographic functional
residual capacity (FRC) above either ULN or 120 % of pre-
dicted is termed lung hyperinflation. An increase in ple-
thysmographic RV exceeding either ULN or 120 % of
predicted is termed pulmonary gas trapping, also expressed
by an increase in the RV/TLC ratio above the ULN. It
should be acknowledged, however, that single-breath inert
gas dilution techniques underestimate TLC (e.g., “alveolar
volume” during lung diffusing capacity measurements), a
phenomenon that increases in tandem with COPD severity
[8]. Conversely, body plethysmography may overestimate
thoracic gas volume in patients with severe and very severe
COPD due to incomplete equilibration of mouth and alveo-
lar pressures, heterogeneity of alveolar pressure swings dur-
ing the panting maneuver, and excessive compliance of the
extrathoracic airway [9]. This error is minimized by ensur-
ing that panting frequency is maintained around 1 Hz.
Total lung capacity
TLC is the greatest volume of gas in the lungs after max-
imal voluntary inspiration. It depends on the static balance
between the outward forces generated by inspiratory mus-
cles during a maximal inspiratory effort and the inward
elastic forces of the chest wall and lung (Fig. 1). At TLC,
these two sets of forces are equal and opposite in sign. The
increase in TLC in COPD usually reflects the increased
lung compliance due to emphysema [10, 11] as thoracic
compliance decreases with senescence [12–14].Fig. 1 Quasistatic V–P curves of lung (PL), chest wall (Pcw), and total respira
forces of lung and chest wall are indicated by the arrows in the drawings.
opposite is true for the Pcw. The fall in the compliance of the respiratory sy
compliance of the lung, whereas at low lung volume it reflects the decreas
drawing is indicated by the horizontal broken lines. (From: [95])Functional residual capacity at rest
FRC or the lung volume at the end of quiet expiration
during tidal breathing (i.e., EELV) is increased in COPD
compared with health [15]. The term EELV is used inter-
changeably with FRC in the current review. It should be
noted that FRC is not always synonymous with the static
equilibrium volume of the relaxed respiratory system; Vr
is the volume at which the elastic recoil pressures of
lung and relaxed chest wall are equal and opposite in
sign (Fig. 1) [10, 11]. Active or passive mechanisms often
operate to make FRC different from Vr both in health
and in COPD. For example, in healthy younger subjects
during exercise, activation of expiratory muscles com-
monly drives FRC below the Vr [16].
An increase in FRC measured at rest has both static
and dynamic determinants in COPD [17]. Tradition-
ally, an increase in “static” FRC refers to an increase in
Vr due to loss of lung recoil which resets the balance
of forces between the lung and chest wall [10, 11].
Accordingly, the static Vr is higher than that of pre-
dicted normal and FRC is increased in COPD com-
pared with health [1, 6, 15]. In this circumstance the
higher Vr means that the alveolar pressure at end-
expiration remains atmospheric. Interestingly, resting
FRC is also dynamically determined in the setting of
EFL and varies with the breathing pattern. For in-
stance, a tachypneic breathing pattern and/or a high
inspiratory-to-expiratory time ratio will shorten the
time available for adequate lung emptying [17]. Thus,
mouth pressure at EELV is positive - a phenomenon
termed intrinsic positive end-expiratory pressure
(PEEPi) [18]. EELV during spontaneous breathing in
flow-limited patients is a continuous dynamic variabletory system (Prs) during relaxation in a sitting position. The static
PL increases its curvature with increasing lung volume, whereas the
stem at high lung volumes is therefore mainly due to the decrease in
ed compliance of the chest wall. The volume corresponding to each
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breathing frequency are abruptly increased (e.g., volun-
tarily, during anxiety/panic attacks, acute hypoxemia,
physical activity or during metronome pacing);; or b)
EFL is suddenly worsened (e.g., increased broncho-
spasm or during exacerbation) [22–24].
Lung hyperinflation at rest is also influenced by body
position and by body mass: for example, EELV decreases
when adopting a supine position [11] or with obesity
[25, 26]. In this respect, FRC has been shown to de-
crease exponentially with increasing body mass index
(BMI), with the largest changes occurring with BMI in
the overweight to mild obesity range [25].Inspiratory capacity
Inspiratory capacity (IC) is defined as the maximal
volume of air that can be inspired after a quiet expir-
ation to EELV. The resting IC (or IC/TLC ratio) [3]
is also used as an indirect measure of lung hyperin-
flation when TLC is stable [27, 28]. Resting IC
progressively declines as airway obstruction worsens
in COPD (Fig. 2) [29]. Measurement of IC is
motivation-dependent and is influenced by static
strength of the inspiratory muscles and EELV [28].
The IC represents the operating limits for tidal vol-
ume (VT) expansion during exercise in patients with
EFL and influences breathing pattern and peak venti-
latory capacity (see below). The IC is diminished in
the presence of significant inspiratory muscle weak-
ness [30]. Patients with a resting IC of less than
80 % predicted are thought to have significant EFL
during resting breathing and are at greater risk for





















Fig. 2 Inspiratory capacity (IC) decreased linearly as forced expired volume
individuals with airway obstruction. (Constructed with data from: [96])The natural history of lung hyperinflation
Insufficient data from longitudinal studies are available to
precisely chart the natural history of lung hyperinflation in
COPD. Clinical experience indicates this is an insidious
process that occurs over decades. It is acknowledged that
such factors as genetic susceptibility, burden of tobacco
smoke, frequency and severity of exacerbations, and
pathophysiological phenotype collectively dictate the rate of
progression of hyperinflation. A 4-year trial docu-
mented a mean rate of decline in pre-bronchodilator IC of
34–50 mL/year in patients with moderate to very severe
COPD [32]. In that study, patients with the lowest baseline
IC were those with the greatest rates of exacerbation and
death [32]. A cross-sectional study in 2265 patients found
progressive increases in pulmonary gas trapping and lung
hyperinflation (measured by RV and FRC) and a correspond-
ing decline of IC across the continuum of COPD severity
[25]. Lung volume increases were shown to occur even in
the earliest stages of COPD (i.e., GOLD grade 1) and
increased with severity of airway obstruction [25, 29, 33, 34].
Review
Hyperinflation across the continuum of COPD
Small studies in mild COPD have reported increased
static lung compliance, and quantitative computed tom-
ography (CT) scans have shown emphysema and gas
trapping [35–37]. Gas trapping, as assessed by expiratory
CT scans, can exist in the absence of structural emphy-
sema and is believed to indirectly reflect small airway
dysfunction in mild COPD [35]. The presence of lung
hyperinflation assessed by quantitative CT scans was
found to predict a rapid annual decline in FEV1 in
smokers with a normal FEV1 [36]. Corbin and coworkers








in 1 s (FEV1) worsened (r = 0.67, p < 0.0005) in a group of 2265
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compliance. Interestingly, these investigators reported that
increases in TLC in milder COPD led to a preserved slow
vital capacity (VC) and IC in the setting of increased RV
and FRC, respectively [37]. Although there is considerable
heterogeneity in FRC and RV across GOLD grades, many
patients in each GOLD category have values that are above
the predicted normal range [25]. From cross-sectional stud-
ies, it would appear that RV and FRC increase exponentially
as airway obstruction worsens [25].Physiological adaptations to chronic lung hyperinflation
In the presence of lung hyperinflation, functional muscle
weakness is mitigated, to some extent, by long term adap-
tations such as shortening of diaphragmatic sarcomeres
and reduction in sarcomere number which cause a left-
ward shift of the length-tension relationship; thus improv-
ing the ability of the muscles to generate force at higher
lung volumes [11, 38]. In patients with chronic lung
hyperinflation, adaptive alterations in muscle fiber
composition (an increase in the relative proportion of
slow-twitch, fatigue resistant, type I fibers) and oxidative
capacity (an increase in mitochondrial concentration and
efficiency of the electron transport chain) are believed to
preserve the functional strength of the overburdened dia-
phragm and make it more resistant to fatigue [39, 40]. In
this regard, Similowski et al. [41] demonstrated that the
reduction in the pressure-generating capacity of the in-
spiratory muscles of stable COPD patients was related to
lung hyperinflation, but that diaphragmatic function in
such patients was similar to normal subjects when mea-
surements were compared at the same lung volume. Des-
pite these impressive temporal adaptations, the presence
of severe lung hyperinflation means that IC and ventila-
tory reserve in COPD is diminished and the ability to in-
crease VT and _V E is greatly limited when the demand
suddenly rises (e.g., with exercise or exacerbation).Consequences of lung hyperinflation at rest
Respiratory muscle function
A mild increase in EELV at rest might be advantageous
as it improves airway conductance and attenuates ex-
piratory flow limitation to a variable degree. However,
lung hyperinflation in moderate to severe COPD places
the inspiratory muscles, especially the diaphragm, at a
significant mechanical disadvantage by shortening its
fibers, thereby compromising its force generating cap-
acity [42]. Lung hyperinflation also affects the capacity
of the parasternal intercostals and scalenes to shorten
with potential negative consequences [43].
Known mechanisms of compromised diaphragmatic
function secondary to hyperinflation can be summarized
as follows [44, 45]:a) worsening of the length-tension relationship,
b) decrease in the zone of apposition,
c) decrease in the curvature,
d) change in the mechanical arrangement of costal and
crural components, and
e) increase in the elastic recoil of the thoracic cage.
Lung hyperinflation decreases the resting length of the
diaphragm and, less so, the rib cage muscles. The short-
ening of the diaphragm is due to a decrease in the length
of its zone of apposition, which causes a decrease in its
pressure generating capacity [43, 44]. The change in
fiber orientation with lung hyperinflation decreases the
ability of the diaphragm to generate force, and this
muscle has an expiratory rather than inspiratory action
on the rib cage [39, 40, 44, 45].
When EELV represents approximately 70 % of pre-
dicted TLC, thoracic elastic recoil is directed inward
(i.e., increased) so that the inspiratory muscles have to
work, not only against PEEPi and the elastic recoil of the
lungs, but also against the elastic recoil of the thoracic
cage (Fig. 1) [11]. The net effect is a pronounced in-
crease in the work and oxygen (O2) cost of breathing at
rest in patients with severe COPD [46].
Lung hyperinflation and central hemodynamics
Severe hyperinflation, as defined as an IC/TLC ratio <25 %,
has been shown to be associated with increased cardiovas-
cular mortality [3], impaired left ventricular (LV) filling
[47], and reduced exercise tolerance [6, 48]. Severe lung
hyperinflation has been linked to a reduced intra-thoracic
blood volume and reduced LV end-diastolic volume as
assessed by magnetic resonance imaging (MRI) [49]. Barr
et al. reported that in a large population-based sample of
smokers and non-smokers, a 10 % increase in the percent-
age of emphysema (measured by CT) correlated with re-
ductions in LV diastolic volume, stroke volume and cardiac
output, as estimated by MRI [47]. Lung hyperinflation has
also the potential to impair cardiac function by increasing
pulmonary vascular resistance [50]. Increased intrathoracic
pressure swings linked to the increased mechanical loading
of hyperinflation may result in increased LV afterload as a
result of the increased LV transmural pressure gradient
(Fig. 3) [51]. Reductions in venous return, right and left
ventricular volumes, and LV stroke volume are additional
consequences of the altered intra-thoracic pressure gradi-
ents [6, 15].
DH during exacerbations of COPD
The mechanisms of DH are broadly similar during in-
duced bronchoconstriction in asthma and during acute
exacerbations in patients with COPD (AECOPD). How-
ever, patients with COPD, especially those with more se-
vere airway obstruction, are more likely to have significant
Fig. 3 A schematic diagram showing the potential deleterious effects of lung hyperinflation on cardio-pulmonary interactions in patients with
COPD. These interactions may vary according to phase alignment between the respiratory and cardiac cycles. There are also important
modulating effects of volemic status, sympathetic nervous system activation, ventilation-related vagal reflexes and comorbidities (e.g., pulmonary
hypertension and chronic heart failure) which are not depicted. Abbreviations: Circ, circulation; LV, left ventricular; Pab, abdominal pressure; PaCO2,
partial pressure of arterial carbon dioxide; Ppl, pleural pressure; Pulm, pulmonary; Syst, systemic; RV, right ventricular. (From: [15])
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monary gas exchange [5] (Fig. 4). Thus, the consequences
of acute-on-chronic lung hyperinflation in such individ-
uals may be serious and even life-threatening. During
AECOPD, airway resistance is abruptly increased due to a
combination of bronchospasm, mucosal edema and spu-
tum inspissation; which worsens expiratory flow limitation
and compromises effective lung emptying [5]. The in-
creased respiratory neural drive (RND), secondary to at-
tendant ventilation-perfusion abnormalities in the face of
increasing lung hyperinflation, means that patients tend to
adopt a rapid, shallow breathing pattern during an exacer-
bation. This further limits the time available for lung
emptying, thus promoting greater DH in a vicious cycle.
Moreover, subjective fear, anxiety or overt panic related to
distressing dyspnea, with attendant increased sympathetic
nervous system activation, also powerfully influence
breathing pattern to worsen DH and perceived respiratory
discomfort [5].
During AECOPD, the respiratory muscles already
burdened by increased resistive loading become sub-
jected to increased elastic loading, decreased dynamic
lung compliance and functional muscle weakness.
Intrapulmonary pressures are positive at the end of ex-
piration (i.e., increased PEEPi) [52, 53]. PEEPi essen-
tially acts as an inspiratory threshold load and may beas high as 6–9 cm H2O during quiet breathing at rest
in clinically stable patients with severe resting lung
hyperinflation. The short-term clinical consequences of
acute DH in individual patients during AECOPD will
depend on the baseline IC; those with the most severe
resting lung hyperinflation (i.e., lowest IC) can expect
the most negative clinical outcomes. During acute-on-
chronic hyperinflation, PEEPi may rise precipitously
and, together with the increased elastic (related to
breathing at a less compliant part the pressure-volume
relationship) (Fig. 1) and resistive work, collectively in-
crease the overall work and O2 cost of breathing with
development of fatigue or frank respiratory failure [53].
During AECOPD, the mechanical output of the flow-
limited and hyperinflated respiratory system may not
increase in proportion to increasing respiratory neural
drive, resulting in critical neuromechanical dissociation
of the respiratory system which may explain the wors-
ening dyspnea [5, 6]. In fact, dyspnea and functional in-
dices of hyperinflation have been found to improve in
parallel in the recovery phase of acute AECOPD [54].
The major goal in AECOPD is lung deflation by inten-
sive bronchodilator therapy to restore neuromechanical
coupling and relieve dyspnea. Non-invasive mechanical
ventilation with continuous positive airway pressure or
bi-level support can also effectively counterbalance the
Fig. 4 The negative consequences of dynamic hyperinflation during an acute exacerbation of COPD. Dynamic hyperinflation develops as a
consequence of worsening expiratory flow limitation. Abbrevations: EELV, end-expiratory lung volume; IC, inspiratory capacity; PaO2, arterial oxygen
tension; PaCO2, arterial carbon dioxide tension; PEEPi, intrinsic positive end-expiratory pressure; CLdyn, dynamic lung compliance; H
+, hydrogen
ion concentration; LV, left ventricular RV, right ventricular; VD/VT, physiological dead space; V/Q, ventilation/perfusion; VT, tidal volume
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inspiratory muscles and provide important dyspnea
relief [55].
DH during exercise in COPD
Dynamic increases in EELV are inevitable during exer-
cise in patients with significant EFL in the setting of high
ventilatory demand [17]. RND (and ventilatory demand)
is often greatly increased in COPD because of the effect
of increased wasted ventilation (high ventilation/perfu-
sion ratios) [6, 56–58] and, in some instances, significant
arterial hypoxemia and metabolic acidosis secondary to
skeletal muscle deconditioning and/or poor O2 delivery
[6, 59]. RND is increased for any given ventilation in
COPD compared with healthy controls reflecting the in-
creased intrinsic mechanical loads on the inspiratory
muscles and the attendant functional muscle weakness
caused by breathing at high lung volumes. In early exer-
cise, mean inspiratory flow rates and tidal volume in-
crease substantially but expiratory time is often too
short to allow complete gas emptying resulting in DH.
Increases in EELV above resting values by 0.3–0.6 L, on
average, have been shown to occur in as many as 85 %
of patients with moderate to severe COPD during cycle
exercise [21].
In patients with advanced COPD, patterns of DH
vary widely but the magnitude of increase in EELV isinversely related to the resting IC. Thus, in patients
with a low resting IC due to severe resting hyperinfla-
tion, VT quickly expands during exercise (even in the
absence of DH) to reach a critical minimal IRV – a
true mechanical limit where further increases in venti-
lation soon become impossible [60, 61]. DH during ex-
ercise is even present in many individuals with mild
airway obstruction (and dominant peripheral airways
disease) as a result of the combined effects of higher
ventilatory inefficiency and dynamic expiratory flow
limitation [34, 62]. DH occurs in the face of vigorous
expiratory muscle effort and likely occurs “passively”
rather than by active inspiratory muscle braking
throughout the respiratory cycle [63]. Guenette et al.
found that non-hyperinflators (15 % of the large multi-
center group) had similar baseline characteristics
compared with FEV1-matched hyperinflators. These
results suggest that dyspnea intensity was related
to the constraints on VT expansion (reduction in
IRV) and not the magnitude of acute DH during
exercise [64].
Increasing lung hyperinflation as COPD progresses is
associated with increasing reduction of the resting IC [29].
During exercise when VT reaches approximately 70 %
of the prevailing IC (or end-inspiratory lung volume
reaches ~90 % of the TLC at a minimal IRV), there is an
inflection or plateau in the VT/ _V E relation (Fig. 5) [65].
TLC
Fig. 5 Tidal volume (VT), breathing frequency (Fb), dynamic inspiratory capacity (IC) and inspiratory reserve volume (IRV) are shown plotted
against minute ventilation (/ _VE) during constant work rate exercise for each forced expiratory volume in 1 s (FEV1, expressed as % predicted)
quartile (Q). The upper through to lower quartiles (Q1-Q4) represent the mildest to most severe groups, respectively. Note the clear inflection
(plateau) in the VT// _VE relationship which coincides with a simultaneous inflection in the IRV. After this point, further increases in _VE are
accomplished by accelerating Fb. Data plotted are mean values at steady-state rest, isotime (i.e., 2 min, 4 min), the VT// _VE inflection point and
peak exercise. (Modified from: [29])
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further sustainable increases in _VE are impossible in the
face of near maximal ventilatory drive. The inability to fur-
ther expand VT is associated with tachypnea – the only
remaining strategy available in response to the increasing
ventilatory drive. As explained above, increased breathing
frequency results in increased elastic loading due to fur-
ther DH and the increased velocity of shortening of the in-
spiratory muscles, with associated functional weakness
and decreased dynamic lung compliance. In this setting,
RND (indirectly assessed by diaphragm electromyography
(EMGdi)) reaches >70 % of the maximal possible value
and tidal esophageal pressure swings increase to about
50–60 % of the maximal value [62, 66]. The work and O2
cost of breathing required to achieve a given increase in _V
E steadily increases to a high percentage of the total O2
uptake [46]. These collective derangements can predispose
to critical inspiratory muscle functional weakness, fatigue
or even overt respiratory insufficiency with carbon dioxide
(CO2) retention [21, 67].Cardio-circulatory consequences of exercise DH
DH adversely affects dynamic cardiac function by con-
tributing to pulmonary hypertension (intra-alveolar ves-
sel compression), by reducing right ventricular pre-load(reduced venous return) and, in some cases, by increas-
ing left ventricular afterload [6, 51]. In the absence of
cardiac disease, cardiac output has been found to in-
crease normally as a function of oxygen uptake during
submaximal exercise in COPD, although stroke volume
is generally smaller and heart rate correspondingly
higher than in health [68, 69]. Of note, peak cardiac
output reaches a lower maximal value during exercise
in COPD, which may be due, in part, to abnormal ven-
tilatory mechanics [6]. There is also evidence that im-
paired cardiac output response in the rest-to-exercise
transition in non-hypoxemic patients with moderate-
to-severe COPD is associated with increased muscle
deoxygenation thereby suggesting reduced muscle per-
fusion [59]. Of note, reducing resting hyperinflation
with bronchodilators improved muscle oxygenation
during exercise [70, 71], a finding related to a faster
cardiac output adjustment to exercise [71]. It has also
been postulated that competition between the over-
worked ventilatory muscles and the active peripheral
muscles for a reduced cardiac output may compromise
blood flow and oxygen delivery to the latter, with nega-
tive consequences for exercise performance [72–74].
The impact of DH on cardiac output and ventilatory/
locomotor muscle competition during exercise merits
further study.
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dyspnea
Dyspnea is a common symptom in patients with COPD
across the continuum of the disease and is often the prox-
imate cause of exercise limitation. The increase in dyspnea
intensity at any given ventilation as COPD severity in-
creases (compared to health), reflects the progressively in-
creasing intrinsic mechanical loading of the respiratory
muscles [7, 75]. The rise in dyspnea intensity ratings dur-
ing exercise correlates strongly with indirect indices of in-
creased respiratory neural drive (central motor command
output) such as tidal electromyographic activation of the
diaphragm relative to maximum, tidal esophageal pressure
swings relative to maximum, and ventilation relative to
peak ventilatory capacity [66, 76]. It is postulated that the
amplitude of central neural drive (originating from motor
cortical and medullary centers in the brain) to the respira-
tory muscles is sensed via neural inter-connections (i.e.,
central corollary discharge) between cortical motor and
medullary centers in the brain and the somato-sensory
cortex [75, 77].
Dyspnea intensity is more closely correlated with the
reduction in IRV during exercise than the change in
EELV (i.e., DH) per se [62]. The VT/ _VE inflection corre-
sponds with the IRV/ _VE inflection during exercise and
marks the point where VT expands to reach approxi-
mately 70 % of the prevailing IC and dyspnea intensity
sharply increases (Fig. 6); it also coincides with the point
where the dominant descriptor of dyspnea changes from
increased effort to unsatisfied inspiration [33, 63]. The
VT inflection point, therefore, represents the onset of a
widening disparity between increasing central neural
drive and the mechanical/muscular response of the re-
spiratory system [21, 65]. In advanced COPD, the ratio
of respired effort (and presumably neural drive) to VT
increases steeply from rest to peak exercise, reflectingFig. 6 Relationships between exertional dyspnea intensity and ventilation a
during symptom-limited cycle exercise in COPD. There is a progressive incr
the VT/IC ratio plateaus (corresponding to the VT inflection point), dyspnea
based on forced expiratory volume in 1 s (FEV1) expressed as percent pred
16.5–34.9). Data plotted are mean values at steady-state rest, isotime (i.e., 2progressive neuromechanical dissociation of the respira-
tory system [67]. Exertional dyspnea intensity closely
correlates with indices of effort-volume displacement
dissociation (e.g., the ratio of Pes/PImax to VT/predicted
VC) [65]. The corollary is that effective relief of dyspnea
in COPD following bronchodilators [78, 79] or lung vol-
ume reduction surgery [80] are largely explained by par-
tial restoration of effort-displacement ratios and reduced
neuromechanical dissociation.
Bronchodilator therapy
Effects on lung hyperinflation at rest
Bronchodilators reduce airway smooth muscle tone and
airway resistance, improve airflow, and accelerate the
mechanical time constants for lung emptying [81]. In
this way, inhaled bronchodilators favorably alter the
dynamically-determined components of resting lung
hyperinflation and help deflate the overinflated lung.
Bronchodilators of all classes and duration of action
have consistently been shown to decrease lung hyperin-
flation and pulmonary gas trapping, with reciprocal in-
creases in IC and VC in patients with COPD [82, 83].
Since spirometric measurements are simple to perform,
changes in IC have often been used to track changes in
EELV both at rest and throughout exercise. However,
bronchodilator-induced improvements in IC may under-
estimate the reduction in resting EELV since TLC has been
shown to fall by a small amounts (0.1–0.2 L) [84]. As single
agents, both classes of inhaled bronchodilators (β2-agonists
and muscarinic antagonists) have been shown to increase
the resting IC in patients with COPD by approximately
0.2–0.4 L or 10–15 % (as reviewed in reference [83] and,
more recently, in reference [85]). The largest post-
bronchodilator improvements in IC are seen in patients
with the greatest resting lung hyperinflation (e.g., baseline
IC <80 % predicted) [84]. Decreases in lung volume of thend the ratio of tidal volume to inspiratory capacity (VT/IC) are shown
ease in the dyspnea/ventilation curve with worsening disease. After
rises steeply to intolerable levels. Quartiles (Q) of COPD severity are
icted (ranges: Q1 = 54.5–85.1; Q2 = 43.8–54.1; Q3 = 34.9–43.6; Q4 =
min, 4 min), the VT/ _VE inflection point and peak exercise. (From: [29])
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ated with reduced intrinsic mechanical loading and in-
creased functional strength of the respiratory muscles [15].
Such mechanical improvements are particularly important
in dyspneic patients with more severe COPD who gain the
greatest subjective benefit [75].
Improvement in FEV1 following a bronchodilator, espe-
cially in more advanced COPD, commonly indicate lung
volume recruitment (increased VC) as a result of reduced
pulmonary gas trapping (decreased RV). Thus, studies
have shown a preserved or decreased FEV1/FVC ratio in
response to all classes of bronchodilators [83]. This pat-
tern of lung volume recruitment is noted particularly in
patients with more severe lung hyperinflation [81, 84].
Moreover, a lack of change in FEV1 after bronchodilator
treatment does not necessarily reflect a lack of change in
lung hyperinflation or associated subjective benefits for
the patient [81, 84].
The combination of a long-acting muscarinic antagonist
(LAMA) and a long-acting β2-agonist (LABA) can have
additive effects on reducing lung hyperinflation [86, 87].
Van Noord et al. [86] were the first to study the
combined effect of two long-acting bronchodilators
(tiotropium and formoterol) on IC over a 24-hour
period in patients with moderate-to-severe COPD.
After the 2-week treatment periods, they confirmed
additive effects on lung deflation with significant
increases in average daily IC and daytime peak IC with
the combination treatment versus tiotropium alone.
Importantly, the mechanical benefits were also evident
throughout the night. More recent studies have also
shown slightly greater improvements in resting lung
hyperinflation (increases in IC) with long-acting bron-
chodilator combinations or fixed-dose dual products
such as indacaterol/tiotropium [88] and indacaterol/
glycopirronium [89] over tiotropium monotherapy.Effects on lung hyperinflation during exercise
There has recently been interest in measuring increases in
IC as a surrogate measure of lung deflation during exercise
in response to bronchodilator treatment in COPD [28, 81].
As mentioned, a post-bronchodilator increase in IC indi-
cates reduced elastic/inspiratory threshold loading of the
inspiratory muscles, an important determinant of dyspnea
[6]. By increasing resting IC, bronchodilators also increase
the available dynamic IRV and thereby delay the onset of
critical respiratory-mechanical constraints on VT expansion
(and thereby _VE) during exercise [60, 78, 79, 90, 91]. Thus,
throughout exercise, less respiratory muscle effort is re-
quired to achieve greater tidal volume expansion: the dis-
sociation between central respiratory drive and the
mechanical response of the respiratory system is partially
reversed. Improvements in dyspnea and exercise toleranceafter bronchodilators are closely related to this release of
VT restriction and enhanced neuromechanical coupling of
the respiratory system [65]. Thus, for any given exercise in-
tensity or _VE, patients breathe on the more linear portion
of the respiratory system’s pressure-volume curve, which
delays the onset of neuromechanical dissociation and the
attendant dyspnea [60, 78, 79, 90].Effects on dyspnea and exercise endurance
Randomized controlled trials have examined the effects
of LABA, LAMA and LABA/LAMA combinations on
dyspnea intensity ratings during exercise and/or dyspnea
related to activities of daily living in patients with moder-
ate-to-severe COPD [78, 79, 90, 92]. Bronchodilator-
induced improvements in perceived dyspnea intensity
during constant work rate cycle exercise are variable, pos-
sibly due to measurement variability in this outcome as
well as the modest numbers of patients in many of these
studies. Despite variability in improvements in exertional
dyspnea, increases in IC at a standardized time near end-
exercise (isotime) and in exercise endurance time with
long-acting bronchodilators compared with placebo ap-
pear to be more consistent (Fig. 7) [83]. Increases in cycle
exercise endurance time in response to bronchodilator
therapy are in the order of 20 %, on average [83]. Such in-
creases in cycling endurance time are typically within the
range that is thought to be clinically important, i.e., about
100 s [93, 94]. It is possible that LABA/LAMA fixed-dose
combinations may extend the improvements seen with
single agents [89], however, there is currently limited infor-
mation on exercise responses with dual bronchodilator
therapy. It is to be anticipated that the effects of inhaled
dual LABA/LAMA bronchodilator agents will be most pro-
nounced in patients with more severe resting lung hyperin-
flation and troublesome persistent dyspnea.Conclusions
Summary and clinical relevance
Our understanding of the cause and consequences of lung
hyperinflation in patients with COPD has considerably ad-
vanced in the last decade. It is now well established that
lung hyperinflation and its effects provide a compelling
physiological basis for the subjective experience of breath-
ing discomfort during both exacerbations and physical ac-
tivity in patients with COPD. It is now understood how
acute-on-chronic lung hyperinflation in these clinical set-
tings can abruptly undermine the normal functioning of
the respiratory and cardio-circulatory systems with conse-
quent negative clinical consequences. The corollary is that
partial reversal of lung hyperinflation by pharmacotherapy
and other interventions can effectively mitigate such nega-
tive effects. Thus, a persuasive case can be made to
support the inclusion of indices of lung hyperinflation as
LABA LAMA LABA/LAMA
0 30 60 90 120 150 180
Endurance time (sec)















IC at isotime (L)
-2.0-1.5-1.0-0.50.0













Fig. 7 Improvements in response to long-acting ß2-agonists (LABA), long-acting muscarinic antagonists (LAMA) and LABA/LAMA combinations
compared with placebo are shown for exercise measurements of inspiratory capacity (IC) at a standardized time during exercise (isotime),
constant-work rate cycle exercise endurance time, and dyspnea intensity ratings at isotime. Treatment differences in these randomized,
placebo-controlled studies are statistically significant (p < 0.05) unless indicated otherwise (NS, not significant)
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important clinical outcomes such as mortality, risk of
exacerbation, activity-related dyspnea and exercise
intolerance. Ideally, comprehensive characterization of
physiological impairment in individual symptomatic
patients with COPD should incorporate measures of
lung hyperinflation. The exclusive reliance of spiro-
metric forced expiratory flow rates to evaluate efficacy
of bronchodilators in clinical trials in the past has led
to underestimation of their clinical benefits, particu-
larly in patients with more advanced COPD. In this
context, the increasing use of direct or indirect mea-
sures of lung hyperinflation in assessment of patients
with COPD and their response to pharmacotherapy in
clinical and research settings represents a welcome
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